2016 American Transplant Congress
Enabled PRA and Precision PRA: Alternatives to cPRA as Desensitization Trial Endpoints.
U of Cincinnati, Cincinnati; Mayo Clinic Scottsdale, Scottsdale.
Transplant (Transplant) rate is an optimal endpoint in desensitization (DS) trials in HLA sensitized Txp candidates, however, for waitlisted Txp candidates, wait time heterogeneity compromises…2016 American Transplant Congress
Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).
1Houston Methodist Hospital, Houston, TX; 2Kansas University Medical Center, Kansas City, KS.
Intravenous immune globulin (IVIG) may be beneficial for pre-emptive treatment of de novo DSA in RTR without biopsy-proven acute rejection (AR). Herein, we present long-term…2016 American Transplant Congress
MHC/HLA-Specific IgE in Allotransplantation.
Background: Donor-specific antibodies (DSA) are recognized as important factors in determining outcome in renal transplantation.Typically DSAs of the IgG isotype are measured, but little is…2016 American Transplant Congress
The Effect of Tocilizmab Treatment (TCZ-Rx) on Total IgG and Anti-CMV-IgG Levels in HLA-Sensitized (HS) Kidney Transplant Patients.
Background: TCZ has anti-B cell and anti-inflammatory properties. We have reported its successful use for pre-transplant (Tx) desensitization (DES) and treatment of ABMR. We also…2016 American Transplant Congress
Inhibitory FcγRIIB Functionally Inhibits Donor-Reactive CD8+ Memory T Cell Responses Following Transplantation.
Emory Transplant Center, Emory University, Atlanta, GA.
Fc receptors are expressed by many types of immune cells and bind to the constant portion of immunoglobulin to mediate their effector functions. The inhibitory…2015 American Transplant Congress
The Effects of Donor Specific Anti- Human Leukocyte Antigen Antibodies Late After Heart Transplantation
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: The development of anti-HLA antibodies following heart transplantation has been associated with poor outcomes, including lower survival and increased risk for the development of…2015 American Transplant Congress
CMV IgG Provides Similar Anti-CMV Efficacy as Valganciclovir in High-Risk Organ Transplant Recipients, With Reduced Costs
Abdominal organ transplants at high risk for CMV infection (D+/R-) remain a difficult cohort to prevent late CMV infection despite prolonged valganciclovir (VGC) administration. Administration…2015 American Transplant Congress
Natural History of Anti- Human Leukocyte Antigen Antibodies After Hear Transplant
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: The natural history of the production of circulating antibodies has not yet been clearly established. Recent technology has allowed for the improved detection of…2015 American Transplant Congress
The Use of Eculizumab to Treat the Highly Sensitized Patient Awaiting Heart Transplant
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Highly sensitized patients (pts) awaiting heart transplantation remain a significant challenge due to prolonged often prohibitive wait times for suitable organs and increased rejection…2015 American Transplant Congress
The Molecular Landscape of Atrophy-Fibrosis in Human Kidney Transplants: The Dominant Role of Acute Parenchymal Injury
University of Alberta, Edmonton, Canada.
We studied the effect of time post-transplant on atrophy-fibrosis (AF) and molecular associations with AF in 703 kidney transplant indication biopsies (bx) 3 days to…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- Next Page »